Literature DB >> 15853479

Suicidal behavior in schizophrenia.

Rajiv Tandon1.   

Abstract

There is a high prevalence of suicidal behavior in individuals suffering from schizophrenia and recent investigations substantially elucidate this problem and provide useful insights about clinical risk factors, neurobiologic underpinnings and the impact of various treatments on reducing such behavior. The risk of suicide is greatest early in the course of schizophrenic illness but continues throughout life; risk factors for suicidal behavior include psychosis, depression and substance abuse. Effectively treating positive symptoms and depression, reducing substance abuse, avoiding akathisia, addressing demoralization and instilling hope are important elements in this treatment approach. The newer generation of atypical antipsychotics (particularly clozapine) and new psychologic approaches (particularly cognitive behavioral therapy) appear to be useful in reducing suicidality in schizophrenia. The significant advances in defining the neurobiologic basis of suicidality may enable the development of more effective treatments. The renewed emphasis on resilience and recovery as desired outcomes in schizophrenia and the accompanying sense of hope encourage optimism about effectively reducing suicidality in schizophrenia. Over the past 10 years, much has been learnt and hopefully this momentum will be translated into increasingly better outcomes.

Entities:  

Mesh:

Year:  2005        PMID: 15853479     DOI: 10.1586/14737175.5.1.95

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  2 in total

1.  Differing correlates for suicide attempts among patients with schizophrenia or schizoaffective disorder in India and USA.

Authors:  Triptish Bhatia; Pramod Thomas; Prachi Semwal; B K Thelma; V L Nimgaonkar; Smita N Deshpande
Journal:  Schizophr Res       Date:  2006-06-15       Impact factor: 4.939

2.  From ideation to attempt: A study of suicidality and its correlates amongst patients with schizophrenia in a resource-poor country.

Authors:  Oluseun P Ogunnubi; Francis O Aina; Cecilia O Busari; Olamijulo Fatiregun; Babatunde Fadipe; Abosede A Adegbohun; Osunwale D Oni
Journal:  S Afr J Psychiatr       Date:  2022-01-27       Impact factor: 1.550

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.